1. Home
  2. ESNT vs LQDA Comparison

ESNT vs LQDA Comparison

Compare ESNT & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Essent Group Ltd.

ESNT

Essent Group Ltd.

HOLD

Current Price

$67.23

Market Cap

5.9B

Sector

Finance

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$66.68

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESNT
LQDA
Founded
2008
2004
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
5.5B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
ESNT
LQDA
Price
$67.23
$66.68
Analyst Decision
Buy
Strong Buy
Analyst Count
7
11
Target Price
$67.29
$41.00
AVG Volume (30 Days)
506.9K
1.0M
Earning Date
05-08-2026
05-08-2026
Dividend Yield
2.19%
N/A
EPS Growth
0.73
51.81
EPS
3.89
1.26
Revenue
$1,260,935,000.00
$158,320,000.00
Revenue This Year
$1.12
$278.87
Revenue Next Year
$3.37
$57.13
P/E Ratio
$17.35
$54.28
Revenue Growth
1.45
1031.18
52 Week Low
$55.34
$21.15
52 Week High
$70.37
$93.61

Technical Indicators

Market Signals
Indicator
ESNT
LQDA
Relative Strength Index (RSI) 44.55 41.28
Support Level $67.27 $30.48
Resistance Level $70.13 $92.35
Average True Range (ATR) 1.21 2.64
MACD -0.28 0.33
Stochastic Oscillator 28.99 51.45

Price Performance

Historical Comparison
ESNT
LQDA

About ESNT Essent Group Ltd.

Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: